Profile picture

Associate Professor Daniele Pastori

Sapienza University of Rome, Rome (Italy)
Follow
Biography
Daniele Pastori is a MD and Associate Professor of Internal and Emergency Medicine at Sapienza University of Rome, Italy. He has been working on thrombosis and anticoagulant therapy since 2014. He co-authored >200 publications on clinical and translational research on cardiovascular and thrombotic diseases such as atrial fibrillation, antiphospholipid syndrome, heart valves, ischemic heart disease and venous thromboembolism.
Logo ESC

Contributor content

A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.
Presentation
A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.
Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.
Presentation
Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.
Bleeding and thrombotic events in patients with atrial fibrillation and cancer: a systematic review and meta-regression analysis.
Presentation
Bleeding and thrombotic events in patients with atrial fibrillation and cancer: a systematic review and meta-regression analysis.
Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: A nationwide cohort study
Presentation
Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: A nationwide cohort study
C: Cardiovascular risk factor and comorbidity optimisation (including lifestyle changes).
Presentation
C: Cardiovascular risk factor and comorbidity optimisation (including lifestyle changes).
Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer.
Presentation
Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer.
Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study.
Presentation
Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study.
Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.
Presentation
Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.
Comparison of bleeding risk scores in patients with atrial fibrillation and cancer.
Presentation
Comparison of bleeding risk scores in patients with atrial fibrillation and cancer.
Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device
Presentation
Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device

ESC 365 is supported by